Evidence map›Paper›PMID 42471753›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

The design of embedded pragmatic clinical trials: methodological developments and statistical lessons learned from the first cycle of the NIA IMPACT collaboratory.

Thomas G Travison, Kendra Davis-Plourde, Keith S Goldfeld, Fan Li, Yifan Lou, Joan K Monin, Monica Taljaard, Jeffrey Turner, Ana-Maria Vranceanu, Heather G Allore

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thomas G TravisonCenter for Analytic Sciences in Aging, Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.
Kendra Davis-PlourdeDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Keith S GoldfeldDivision of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
Fan LiDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Yifan LouSchool of Social Work, Virginia Commonwealth University, Richmond, Virginia, USA.
Joan K MoninDepartment of Social and Behavioral Sciences, Yale School of Public Health, New Haven, Connecticut, USA.
Monica TaljaardMethodological and Implementation Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Jeffrey TurnerCenter for Gerontology & Healthcare Research, Brown University School of Public Health, Providence, Rhode Island, USA.
Ana-Maria VranceanuOffice of Research Careers, Center for Academic Development and Enrichment, Mass General Brigham Academic Medical Centers, Boston, Massachusetts, USA.
Heather G AlloreDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-7685-8175

Funding

Training Core (I)U54AG063546 · NIA · BROWN UNIVERSITY · PI JOSEPH E. GAUGLER · 2019 to 2026
$125.9M
NIH HHS U54AG063546
6 · The paper itself

Abstract

introductionThe National Institute on Aging-funded IMbedded Pragmatic Alzheimer's disease and AD-Related Dementias Clinical Trials (IMPACT) Collaboratory was established to build capacity for conducting embedded pragmatic clinical trials (ePCTs) within healthcare systems for people living with dementia and their care partners. Here we present methodology and describe lessons learned from the first five years of IMPACT's Design and Statistics Core (DSC).

methodsThe DSC assembled a multidisciplinary team focused on advancing the design, analysis, and implementation of ePCTs.

resultsThe DSC developed and disseminated methods for design and sample size of cluster randomized designs with complex correlation structures; guidance for pilot ePCTs; approaches to patient-care partner ePCTs; approaches to testing health-equity-relevant hypotheses; and guidance for training quantitative and clinical scientists developing ePCTs. DISCUSSION: Key gaps remain in applying dyadic designs and when studying heterogeneity of treatment effects, which will be major priorities for the next funding cycle.

Indexed as

Alzheimer DiseasePragmatic Clinical Trials as TopicResearch DesignHumansNational Institute on Aging (U.S.)United Statesanalytic methodscluster randomized trialsdyadic trial designpragmatic clinical trialssample size calculation

Identifiers

PMID42471753
PMCPMC13380667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.